News: $HZNP Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases FullâYear 2019 Net Sales and Adjusted EBITDA Guidance
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million; KRYSTEXXA ® Second-Quar...